LaFleur & Godfrey LLC Sells 328 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

LaFleur & Godfrey LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,969 shares of the company’s stock after selling 328 shares during the period. LaFleur & Godfrey LLC’s holdings in IDEXX Laboratories were worth $5,037,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Clearbridge Investments LLC increased its position in IDEXX Laboratories by 696.0% during the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after purchasing an additional 308,493 shares during the period. Vontobel Holding Ltd. boosted its position in IDEXX Laboratories by 3,325.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock valued at $111,229,000 after acquiring an additional 213,731 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after acquiring an additional 177,226 shares during the period. 1832 Asset Management L.P. raised its position in shares of IDEXX Laboratories by 4,193.1% in the 2nd quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock worth $62,601,000 after acquiring an additional 125,498 shares in the last quarter. Finally, Jupiter Asset Management Ltd. purchased a new position in shares of IDEXX Laboratories in the 1st quarter valued at approximately $55,425,000. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on IDXX. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Piper Sandler lowered their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Finally, BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $7.95 during mid-day trading on Wednesday, reaching $465.97. 369,640 shares of the stock traded hands, compared to its average volume of 467,566. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business’s 50-day moving average is $488.55 and its 200-day moving average is $492.71. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The stock has a market capitalization of $38.48 billion, a PE ratio of 45.88, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the company earned $2.67 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.